These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 1812365)

  • 1. Physiological principles for the design of hepatic contrast agents.
    Stark DD
    Magn Reson Med; 1991 Dec; 22(2):324-8; discussion 343-6. PubMed ID: 1812365
    [No Abstract]   [Full Text] [Related]  

  • 2. How can superparamagnetic iron oxides be used to monitor disease and treatment?
    Unger EC
    Radiology; 2003 Dec; 229(3):615-6. PubMed ID: 14657295
    [No Abstract]   [Full Text] [Related]  

  • 3. Target-specific superparamagnetic MR contrast agents.
    Weissleder R
    Magn Reson Med; 1991 Dec; 22(2):209-12; discussion 213-5. PubMed ID: 1812348
    [No Abstract]   [Full Text] [Related]  

  • 4. Overview of contrast enhancement with iron oxides.
    Frija G; Clément O; de Kerviler E
    Invest Radiol; 1994 Jun; 29 Suppl 2():S75-7. PubMed ID: 7928276
    [No Abstract]   [Full Text] [Related]  

  • 5. Ferromagnetic particles as contrast agents for magnetic resonance imaging of liver and spleen.
    Mendonca Dias MH; Lauterbur PC
    Magn Reson Med; 1986 Apr; 3(2):328-30. PubMed ID: 3713497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver. II: Iron oxide-based reticuloendothelial contrast agents for MR imaging. Clinical review.
    Petersein J; Saini S; Weissleder R
    Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):53-60. PubMed ID: 8673716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relaxation enhancement of the dog liver and spleen by biodegradable superparamagnetic particles in proton magnetic resonance imaging.
    Hemmingsson A; Carlsten J; Ericsson A; Klaveness J; Sperber GO; Thuomas KA
    Acta Radiol; 1987; 28(6):703-5. PubMed ID: 2962602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SHU 555A. A new superparamagnetic iron oxide contrast agent for magnetic resonance imaging.
    Hamm B; Staks T; Taupitz M
    Invest Radiol; 1994 Jun; 29 Suppl 2():S87-9. PubMed ID: 7928280
    [No Abstract]   [Full Text] [Related]  

  • 9. Superparamagnetic iron oxide for liver imaging. Comparison among three different preparations.
    Bach-Gansmo T; Fahlvik AK; Ericsson A; Hemmingsson A
    Invest Radiol; 1994 Mar; 29(3):339-44. PubMed ID: 8175309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Transmission electron microscopy in the structural study of superparamagnetic contrast agents for MRI].
    Lucet I; Filmon R; Pouliquen D; Le Jeune JJ; Jallet P
    Bull Assoc Anat (Nancy); 1994 Mar; 78(240):57-9. PubMed ID: 7519906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Superparamagnetic particles as an oral contrast agent in abdominal magnetic resonance imaging.
    Oksendal AN; Jacobsen TF; Gundersen HG; Rinck PA; Rummeny E
    Invest Radiol; 1991 Nov; 26 Suppl 1():S67-70; discussion S71. PubMed ID: 1808152
    [No Abstract]   [Full Text] [Related]  

  • 12. Hepatic in vivo video microscopic study for evaluating experimental and approved magnetic resonance contrast agents.
    Kruskal JB; Lunderquist A; Clouse ME
    Invest Radiol; 1994 Jun; 29 Suppl 2():S83-6. PubMed ID: 7928279
    [No Abstract]   [Full Text] [Related]  

  • 13. Imaging of hepatocellular carcinoma: qualitative and quantitative analysis of postvascular phase contrast-enhanced ultrasonography with sonazoid. Comparison with superparamagnetic iron oxide magnetic resonance images.
    Inoue T; Kudo M; Hatanaka K; Takahashi S; Kitai S; Ueda T; Ishikawa E; Hagiwara S; Minami Y; Chung H; Ueshima K; Maekawa K
    Oncology; 2008; 75 Suppl 1():48-54. PubMed ID: 19092272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Focal nodular hyperplasia of the liver: imaging findings with emphasis on the findings of superparamagnetic iron oxide-enhanced MR imaging].
    Han JK; Kim SH
    Korean J Hepatol; 2006 Mar; 12(1):116-9. PubMed ID: 16565614
    [No Abstract]   [Full Text] [Related]  

  • 15. Early radiation effects on the liver demonstrated on superparamegnetic iron oxide-enhanced T1-weighted MRI.
    Mori H; Yoshioka H; Ahmadi T; Saida Y; Ohara K; Itai Y
    J Comput Assist Tomogr; 2000; 24(4):648-51. PubMed ID: 10966203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Magnetic resonance imaging of the liver: what kind of contrast agents?].
    De Gaspari A; De Cobelli F; Del Maschio A
    Radiol Med; 2001 Sep; 102(3):109-21. PubMed ID: 11677451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of fast and ultrafast T2-weighted MR imaging sequences in hepatic enhancement with ferumoxides: comparison with conventional spin-echo sequence.
    Abe Y; Yamashita Y; Namimoto T; Tang Y; Takahashi M
    Radiat Med; 2000; 18(2):97-105. PubMed ID: 10888042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MR enhancement of hepatoma by superparamagnetic iron oxide (SPIO) particles.
    Yamamoto H; Yamashita Y; Yoshimatsu S; Baba Y; Takahashi M
    J Comput Assist Tomogr; 1995; 19(4):665-7. PubMed ID: 7622710
    [No Abstract]   [Full Text] [Related]  

  • 19. Area of paradoxical signal drop after the administration of superparamagnetic iron oxide on the T2-weighted image of a patient with lymphangitic metastasis of the liver.
    Lee Y; Lee JS; Kim CM; Jeong JY; Choi JI; Kim MJ
    Magn Reson Imaging; 2008 May; 26(4):577-82. PubMed ID: 18093780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real enhancement or merely increased contrast?
    Chen JH
    AJR Am J Roentgenol; 1997 Jan; 168(1):279-80. PubMed ID: 8976963
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.